Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.57 |
| ▸ | LCK | P06239 | 7/20 | 0.56 |
| ▸ | KDR | P35968 | 3/20 | 0.56 |
| ▸ | JAK3 | P52333 | 2/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.56 |
| ▸ | TNK2 | Q07912 | 8/20 | 0.53 |
| ▸ | MAP4K2 | Q12851 | 8/20 | 0.53 |
| ▸ | ABL1 | P00519 | 3/20 | 0.53 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.52 |
| ▸ | BMX | P51813 | 4/20 | 0.52 |
| ▸ | TEK | Q02763 | 2/20 | 0.52 |
| ▸ | SRC | P12931 | 2/20 | 0.52 |
| ▸ | FES | P07332 | 1/20 | 0.52 |
| ▸ | RET | P07949 | 1/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.52 |
| ▸ | KIT | P10721 | 1/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.52 |
| ▸ | FLT1 | P17948 | 1/20 | 0.52 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30338817 | 1.00 | SYK (0.57) | SYKLCKKDRJAK3MAPK14 | |
| SCHEMBL3134722 | 0.90 | TNK2 (0.65) | SYKLCKTNK2MAP4K2ABL1 | |
| SCHEMBL3139779 | 0.90 | TNK2 (0.62) | SYKLCKKDRJAK3MAPK14 | |
| SCHEMBL3144232 | 0.88 | SYK (0.56) | SYKLCKKDRTNK2MAP4K2 | |
| SCHEMBL3143228 | 0.88 | KDR (0.52) | SYKLCKKDRMAPK14TNK2 | |
| SCHEMBL3132833 | 0.88 | SYK (0.59) | SYKLCKTNK2MAP4K2ABL1 | |
| SCHEMBL3129666 | 0.87 | TNK2 (0.50) | SYKLCKKDRMAPK14TNK2 | |
| SCHEMBL3139803 | 0.85 | TNK2 (0.57) | MAPK14TNK2MAP4K2ABL1BRAF | |
| SCHEMBL3140918 | 0.83 | RAF1 (0.55) | LCKKDRTNK2MAP4K2ABL1 | |
| SCHEMBL4879885 | 0.81 | LCK (0.66) | SYKLCKKDRJAK3MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651648-A4 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-09-02 | — | — | EP | claimed |
| US-7371750-B2 | Diseases with abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, alpha and beta SAPK2 kinases; antiproliferative; pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-phenylcarbamoyl-phenyl]-amides and pyrrolo[3,2-c]pyridine analogs | IRM LLC (BM) | 2008-05-13 | — | — | US | claimed |
| JP-2007500725-A | — | — | 2007-01-18 | — | — | JP | claimed |
| EP-1651648-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-05-03 | — | — | EP | claimed |
| US-20050222177-A1 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2005-10-06 | — | — | US | claimed |
| WO-2005011597-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-02-10 | — | — | WO | claimed |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2022-09-20 | — | — | US | disclosed |
| US-20190183843-A9 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS, INC. (CA) | 2019-06-20 | — | — | US | disclosed |
| US-20190175541-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS, INC. (CA) | 2019-06-13 | — | — | US | disclosed |
| US-20180071244-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS INC (CA) | 2018-03-15 | — | — | US | disclosed |
| US-20100234400-A1 | COMPOUNDS THAT MAINTAIN PLURIPOTENCY OF EMBRYONIC STEM CELLS | IRM LLC (BM) | 2010-09-16 | — | — | US | disclosed |
| US-20100234400-A1 | COMPOUNDS THAT MAINTAIN PLURIPOTENCY OF EMBRYONIC STEM CELLS | IRM LLC (BM) | 2010-09-16 | — | — | US | disclosed |
| US-20100234400-A1 | COMPOUNDS THAT MAINTAIN PLURIPOTENCY OF EMBRYONIC STEM CELLS | IRM LLC (BM) | 2010-09-16 | — | — | US | disclosed |
| US-20080221098-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-09-11 | — | — | US | disclosed |
| US-7371750-B2 | Diseases with abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, alpha and beta SAPK2 kinases; antiproliferative; pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-phenylcarbamoyl-phenyl]-amides and pyrrolo[3,2-c]pyridine analogs | IRM LLC (BM) | 2008-05-13 | — | — | US | disclosed |
| US-7371750-B2 | Diseases with abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, alpha and beta SAPK2 kinases; antiproliferative; pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-phenylcarbamoyl-phenyl]-amides and pyrrolo[3,2-c]pyridine analogs | IRM LLC (BM) | 2008-05-13 | — | — | US | disclosed |
| US-7371750-B2 | Diseases with abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, alpha and beta SAPK2 kinases; antiproliferative; pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-phenylcarbamoyl-phenyl]-amides and pyrrolo[3,2-c]pyridine analogs | IRM LLC (BM) | 2008-05-13 | — | — | US | disclosed |
| EP-1651648-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-05-03 | — | — | EP | disclosed |
| US-20050222177-A1 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2005-10-06 | — | — | US | disclosed |
| WO-2005011597-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190175541-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | SYK 1354/4885LCK 1172/4885KDR 2782/4885 |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DCK, CDC7, DNMT1 | SYK 1354/4885LCK 1172/4885KDR 2782/4885 |
| US-20100234400-A1 | COMPOUNDS THAT MAINTAIN PLURIPOTENCY OF EMBRYONIC STEM CELLS | LIFR, ALPG, BMI1 | SYK 4561/4885LCK 3947/4885KDR 3136/4885 |
| US-20180071244-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | SYK 1354/4885LCK 1172/4885KDR 2782/4885 |
| US-20190183843-A9 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | SYK 1354/4885LCK 1172/4885KDR 2782/4885 |
| US-20050222177-A1 | Compounds and compositions as protein kinase inhibitors | BMX, FES, FRK | SYK 11/4885LCK 9/4885KDR 150/4885 |
| US-20080221098-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | BMX, FES, FRK | SYK 11/4885LCK 9/4885KDR 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.